TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
Cai ZhangYaqi DuanMinghui XiaYuting DongYufei ChenLu ZhengShuaishuai ChaiQian ZhangZhengping WeiNa LiuJing WangChaoyang SunZhaohui TangXiang ChengJie WuGuoping WangFang ZhengArian LaurenceBing LiXiang-Ping YangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
These data revealed that TFEB mediates resistance to mTOR inhibition via induction of PD-L1 in human primary RCC tumors, RCC cells, and murine xenograft model. Our data provide a strong rationale to target mTOR and PD-L1 jointly as a novel immunotherapeutic approach for RCC treatment.
Keyphrases
- renal cell carcinoma
- cell proliferation
- electronic health record
- induced apoptosis
- endothelial cells
- big data
- cell cycle arrest
- clinical trial
- single cell
- induced pluripotent stem cells
- oxidative stress
- machine learning
- endoplasmic reticulum stress
- signaling pathway
- pluripotent stem cells
- combination therapy
- data analysis
- pi k akt
- deep learning
- replacement therapy
- smoking cessation